TITLE

Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma

AUTHOR(S)
KATSUNORI KAGOHASHI; HIROAKI SATOH; GEN OHARA; KUNIHIKO MIYAZAKI; MIO KAWAGUCHI; KOICHI KURISHIMA; NOBUYUKI HIZAWA
PUB. DATE
April 2014
SOURCE
Experimental & Therapeutic Medicine;2014, Vol. 7 Issue 4, p1005
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The long-term safety of budesonide/formoterol (BUD/FM) inhalation has not been fully evaluated, particularly in elderly patients with bronchial asthma. To evaluate the 12-month safety of BUD/FM inhalation for elderly asthmatic patients, the changes in serum potassium levels and pulse rate were examined. A retrospective chart review was conducted of consecutive patients who were treated with BUD/FM inhalation (two inhalations of 160/4.5 mg, twice daily; Symbicort Turbuhaler, AstraZeneca) at a hospital between February 2010 and January 2012. A total of 350 patients were treated with BUD/FM inhalation during the study period and were followed up over 12 months. The mean age of the patients was 60 years, and 19.4% and 21.4% of the patients were aged 65-74 years and ≥75 years, respectively. One hundred and fourteen (32.6%) of the 350 patients continued the inhalation therapy for >12 months. Compared with the pretreatment data, reductions in serum potassium levels at 1, 6 and 12 months were not observed, even in the patients aged 65-74 and ≥75 years. There was also no increase in the pulse rate at 1, 6 and 12 months, even in the patients aged 65-74 and ≥75 years. The usual dosage of BUD/FM showed no adverse effects on the serum potassium levels and pulse rate in the adults, including the elderly with persistent asthma.
ACCESSION #
94754506

 

Related Articles

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics